Moneycontrol PRO
HomeNewsBiocon

Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

Jump to
  • Buy Colgate Palmolive, Godrej Consumer; sell Dr Reddy's Labs, Lupin: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com is of the view that one can buy Colgate Palmolive and Godrej Consumer and sell Dr Reddy's Labs and Lupin.

  • USFDA issues Form 483 with 10 observations to Biocon’s Bangalore plant

    USFDA issues Form 483 with 10 observations to Biocon’s Bangalore plant

    Regulatory woes continue for Biocon. The United States Foods and Drug Administration (USFDA) issued a form 483 with 10 observations to the Bangalore plant.

  • Here are Surajit Pal's views on Glenmark Pharma & Biocon

    Here are Surajit Pal's views on Glenmark Pharma & Biocon

    In an interview to CNBC-TV18, Surajit Pal of Prabhudas Lilladher shared his views and readings on two stocks from pharma space - Glenmark Pharma and Biocon.

  • Buy Vedanta, Reliance Industries, Motherson Sumi, Ceat; sell SRF: Sudarshan Sukhani

    Buy Vedanta, Reliance Industries, Motherson Sumi, Ceat; sell SRF: Sudarshan Sukhani

    Sudarshan Sukhani of s2analytics.com is of the view that one may buy Vedanta, Reliance Industries, Motherson Sumi and Ceat and sell SRF.

  • Buy ICICI Prudential, Reliance Capital, Mahanagar Gas: Ashwani Gujral

    Buy ICICI Prudential, Reliance Capital, Mahanagar Gas: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com suggests buying ICICI Prudential, Reliance Capital and Mahanagar Gas.

  • Buy Voltas, Gruh Finance, IGL; sell Punjab National Bank, Delta Corp: Ashwani Gujral

    Buy Voltas, Gruh Finance, IGL; sell Punjab National Bank, Delta Corp: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com is of the view that one can buy Voltas, Gruh Finance and IGL and can sell Punjab National Bank and Delta Corp.

  • Hold Biocon, says Vijay Chopra

    Hold Biocon, says Vijay Chopra

    Vijay Chopra of enochventures.com is of the view that one may hold Biocon.

  • Biocon may test Rs 491: Rajat Bose

    Biocon may test Rs 491: Rajat Bose

    Rajat Bose of rajatkbose.com feels that Biocon may test Rs 491.

  • Bull's Eye: Buy HUL, Biocon, SRF, Godrej Consumer, SPARC, GSFC; Sell Ajanta Pharma

    Bull's Eye: Buy HUL, Biocon, SRF, Godrej Consumer, SPARC, GSFC; Sell Ajanta Pharma

    Ashish Kyal of Waves Strategy Advisors is of the view that one may buy Biocon with a target of Rs 418.

  • Sell Havell, Kwality; buy HUL, Biocon, hold Indo Count Industries: Sudarshan Sukhani

    Sell Havell, Kwality; buy HUL, Biocon, hold Indo Count Industries: Sudarshan Sukhani

    Sudarshan Sukhani of s2analytics.com is of the view that one can sell Havells India and Kwality and buy Hindustan Unilever and Biocon while can hold Indo Count Industries.

  • Buy Dewan Housing Finance, HDFC Bank, Bajaj Finserv: Ashwani Gujral

    Buy Dewan Housing Finance, HDFC Bank, Bajaj Finserv: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com recommends buying Dewan Housing Finance, HDFC Bank and Bajaj Finserv.

  • Buy Britannia Industries; sell UltraTech Cement, Jubilant Foodworks: Ashwani Gujral

    Buy Britannia Industries; sell UltraTech Cement, Jubilant Foodworks: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com is of the view that one can buy Britannia Industries and sell UltraTech Cement and Jubilant Foodworks.

  • Buy Century Plyboards, Brigade Enterprises, HUDCO, Auro Pharma, Biocon: Gujral

    Buy Century Plyboards, Brigade Enterprises, HUDCO, Auro Pharma, Biocon: Gujral

    Ashwani Gujral of ashwanigujral.com suggests buying Century Plyboards, Brigade Enterprises, HUDCO, Aurobindo Pharma and Biocon.

  • Buy Ashok Leyland, Biocon, Dewan Housing Finance: Ashwani Gujral

    Buy Ashok Leyland, Biocon, Dewan Housing Finance: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com recommends buying Ashok Leyland, Biocon and Dewan Housing Finance.

  • Here are SP Tulsian's top trading ideas

    Here are SP Tulsian's top trading ideas

    In an interview to CNBC-TV18's Anuj Singhal and Surabhi Upadhyay, SP Tulsian of sptulsian.com shared his views and outlook on the fundamentals of the market and specific stocks.

  • USFDA boost for Biocon: Analyst view on stock and sector

    USFDA boost for Biocon: Analyst view on stock and sector

    The United States Foods and Drug Administration (USFDA) Oncologic Drugs Advisory Committee (ODAC) has recommended an approval of a biosimilar trastuzumab in the US. Trastuzumab is Biocon and Mylan's biosimilar which is a biosimilar version of Herceptin used to treat breast cancer in the US market. Watch accompanying video of Vishal Manchanda of Nirmal Bang Institutional Equities in which he shared his readings and views on the same.

  • Buy Biocon, Aurobindo Pharma on every dip; sell Axis Bank, Adani Ports: Ashwani Gujral

    Buy Biocon, Aurobindo Pharma on every dip; sell Axis Bank, Adani Ports: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com is of the view that one can buy Biocon and Aurobindo Pharma on every dip and advises selling Axis Bank and Adani Ports.

  • What does today's oncology's drugs advisory panel meet mean for Biocon? CLSA explains

    What does today's oncology's drugs advisory panel meet mean for Biocon? CLSA explains

    The committee will discuss biosimilarity of the product and label extrapolation application by Mylan/Biocon given that they have conducted clinical trials on only one of the three indications, said CLSA.

  • Buy ICICI Bank, Interglobe Aviation, Gruh Finance, Uflex, Equitas Holdings: Gujral

    Buy ICICI Bank, Interglobe Aviation, Gruh Finance, Uflex, Equitas Holdings: Gujral

    Ashwani Gujral of ashwanigujral.com recommends buying ICICI Bank, Interglobe Aviation, Gruh Finance, Uflex and Equitas Holdings.

  • Here are SP Tulsian's top trading ideas

    Here are SP Tulsian's top trading ideas

    In an interview to CNBC-TV18's Anuj Singhal and Varinder Bansal, SP Tulsian of sptulsian.com shared his views and outlook on the fundamentals of the market and specific stocks.

  • Buy Sintex Industries, Biocon, HPCL, Bharti Infratel: Ashwani Gujral

    Buy Sintex Industries, Biocon, HPCL, Bharti Infratel: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com is of the view that one may buy Sintex Industries, Biocon, HPCL and Bharti Infratel.

  • Buy IGL, NTPC, Hexaware Technologies; sell HDIL: Mitessh Thakkar

    Buy IGL, NTPC, Hexaware Technologies; sell HDIL: Mitessh Thakkar

    Mitessh Thakkar of mitesshthakkar.com is of the view that one may buy IGL, NTPC and Hexaware Technologies and can sell HDIL.

  • Biocon gains 13% ahead of US FDA meet to discuss breast cancer drug filing

    Biocon gains 13% ahead of US FDA meet to discuss breast cancer drug filing

    If approved by the regulator, it will be the first Herceptin biosimilar in the US market, a development largely seen as positive for the company.

  • Brokerages largely retain positive stance on Biocon post ANSM observations

    Brokerages largely retain positive stance on Biocon post ANSM observations

    Say the development could be an overhang on the stock, but also bet on the company being a beneficiary of global biosimilar opportunity.

  • Buy, Sell, Hold: 6 stocks and 2 sectors are on analysts’ radar today

    Buy, Sell, Hold: 6 stocks and 2 sectors are on analysts’ radar today

    Lupin, Reliance Industries, and Biocon, among others are being tracked by analysts on Tuesday.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347